A Drug-Drug Interaction Study to Assess the Effect of Rifampin on the Pharmacokinetics of an Oral Dose of BMS-986278 in Healthy Participants
Latest Information Update: 24 Dec 2020
At a glance
- Drugs Admilparant (Primary) ; Rifampicin
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 18 Dec 2018 Status changed from recruiting to completed.
- 25 Oct 2018 New trial record